AAOpt 2025: SightGlass Vision CEO Andrew Sedgwick on what's next for DOT spectacle lenses

Andrew Sedgwick, CEO of SightGlass Vision, provides an in-depth overview of his company's myopia management strategy and current market position during the American Academy of Optometry's Academy 2025 meeting in Boston, Massachusetts.

SightGlass is a relatively new spectacle lens manufacturer specializing in myopia management, with a primary focus on contrast management technology. The most significant highlight of their current research is the 18-month study conducted in China, which demonstrated remarkable results. Specifically, 50-7% of patients showed no meaningful progression of myopia over the entire study period. This data is particularly crucial as China represents the primary market for most myopia management companies.

Strategically, SightGlass Vision is methodically expanding its international footprint. Currently, they have established presence in several markets, including Canada, Israel, Iberia, and a pilot program in the Netherlands. The company is also preparing to enter the UK market in the coming months, with planned activities to support this expansion. In the United States, the company is actively engaged with the FDA, holding a breakthrough device designation. This status provides them enhanced opportunities for communication and potential market access. Sedgwick views the potential US market entry as a significant milestone, believing that spectacle lenses are key to making myopia management more accessible and potentially establishing it as a standard of care in pediatric eye care.

Despite being a small company with fewer than 30 employees, SightGlass Vision is strategically investing in research and development. Their current focus is on advancing contrast management technology, an area of increasing interest in the myopia management field. Sedgwick emphasized that contrast modulation is central to their technological approach and future product development. The company's approach reflects a careful, measured strategy of market expansion, backed by robust clinical research and a commitment to technological innovation. By concentrating on markets with high myopia prevalence and investing in R&D, Sight Glass Vision aims to establish itself as a significant player in the myopia management spectacle lens market.